At Halia Therapeutics, we're committed to delivering innovative treatments while prioritizing patient safety. Our CEO, David Bearss, recently discussed the challenges posed by the FDA's Project Optimus in The Wall Street Journal. While well-intentioned, these new regulations pose significant challenges for smaller biopharma companies like ours. They risk driving innovation overseas due to higher costs and longer timelines. Nevertheless, we remain committed to our core mission: identifying the most effective, lowest doses in early trials to deliver safe and potent treatments to patients. Read more about the impact of these regulations here: https://lnkd.in/eMmnfPKW. #Innovation #Cancer #Biopharma #FDA #HaliaTx
Thanks for the insights David!
Great quote!
Professor of Medicinal Chemistry
2moYes it is a great quote Michael, thank you Dave. Laurence